Company profile
Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07160634 | phase3 | recruiting | 2025-10-22 | 2029-01-01 | Solid Biosciences Inc. | A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) |
| NCT06138639 | phase1_2 | recruiting | 2024-05-06 | 2027-05-06 | Solid Biosciences Inc. | A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) |
| NCT07180355 | phase1 | recruiting | 2025-10-22 | 2028-03-21 | Solid Biosciences Inc. | A Study of SGT-212 Gene Therapy in Friedreich's Ataxia |
| NCT07148089 | phase1 | recruiting | 2026-02-23 | 2027-06-01 | Solid Biosciences Inc. | A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) |
| NCT03368742 | phase1_2 | active_not_recruiting | 2017-12-06 | 2026-10-15 | Solid Biosciences Inc. | Microdystrophin Gene Transfer Study in Adolescents and Children With DMD |
FDA applications (0)
No records yet.